ATE318924T1 - Zwei-schritte-verfahren zur impfung gegen chlamydia - Google Patents

Zwei-schritte-verfahren zur impfung gegen chlamydia

Info

Publication number
ATE318924T1
ATE318924T1 AT99957789T AT99957789T ATE318924T1 AT E318924 T1 ATE318924 T1 AT E318924T1 AT 99957789 T AT99957789 T AT 99957789T AT 99957789 T AT99957789 T AT 99957789T AT E318924 T1 ATE318924 T1 AT E318924T1
Authority
AT
Austria
Prior art keywords
chlamydia
step process
vaccination against
against chlamydia
administration
Prior art date
Application number
AT99957789T
Other languages
English (en)
Inventor
Andrew D Murdin
Robert C Brunham
Original Assignee
Univ Manitoba
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba, Sanofi Pasteur Ltd filed Critical Univ Manitoba
Application granted granted Critical
Publication of ATE318924T1 publication Critical patent/ATE318924T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99957789T 1998-12-04 1999-12-02 Zwei-schritte-verfahren zur impfung gegen chlamydia ATE318924T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11085598P 1998-12-04 1998-12-04

Publications (1)

Publication Number Publication Date
ATE318924T1 true ATE318924T1 (de) 2006-03-15

Family

ID=22335290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957789T ATE318924T1 (de) 1998-12-04 1999-12-02 Zwei-schritte-verfahren zur impfung gegen chlamydia

Country Status (10)

Country Link
US (6) US6676949B2 (de)
EP (1) EP1169465B1 (de)
JP (1) JP2002531135A (de)
AT (1) ATE318924T1 (de)
AU (1) AU772356B2 (de)
CA (1) CA2366462C (de)
DE (1) DE69930147T2 (de)
MX (1) MXPA01005615A (de)
NZ (1) NZ512730A (de)
WO (1) WO2000034498A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
JP4864264B2 (ja) * 1999-12-22 2012-02-01 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
IL158124A0 (en) * 2001-03-29 2004-03-28 Univ Mcgill Leishmania vaccines
ES2451620T3 (es) * 2002-11-07 2014-03-28 Synergy America, Inc. Composiciones y métodos destinados a tratar o prevenir la infección neumocócica
US20070060904A1 (en) * 2005-03-14 2007-03-15 Becton, Dickinson And Company Filling system and method for syringes with short needles
US20120027793A1 (en) 2009-01-29 2012-02-02 British Columbia Cancer Agency Branch Compositions comprising chlamydia antigens
US10258682B2 (en) 2013-01-16 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) * 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
DE3650571T2 (de) 1985-01-14 1997-02-27 Chiron Corp Hauptprotein der Aussenmembran von Chlamydia
US5770714A (en) 1985-01-14 1998-06-23 Washington Research Foundation Chlamydia major outer membrane protein
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
DE69027313T2 (de) * 1989-03-31 1997-01-23 Univ Washington Impfstoffe enthaltende avirulente phop-type mikroorganismen
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
TW201794B (de) * 1991-05-03 1993-03-11 American Cyanamid Co
US5840297A (en) * 1993-03-19 1998-11-24 Johns Hopkins University Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process
NZ276874A (en) * 1993-11-03 1997-11-24 Pfizer Vaccine for treating chlamydia comprising a major outer membrane protein and lipopolysaccharide preparation from a chlamydia organism
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
GB9516293D0 (en) * 1995-08-09 1995-10-11 Immunova Ltee Novel peptides and their use as vaccines
US6001372A (en) * 1995-08-25 1999-12-14 Wisconsin Alumni Research Foundation Antigenic peptides of Chlamydia trachomatis
US6110898A (en) * 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
WO1998002546A2 (en) * 1996-07-12 1998-01-22 University Of Manitoba Dna immunization against chlamydia infection
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
US6344202B1 (en) * 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US6235290B1 (en) * 1997-07-11 2001-05-22 University Of Manitoba DNA immunization against chlaymdia infection
US6696421B2 (en) * 1996-07-12 2004-02-24 University Of Manitoba DNA immunization against chlamydia infection
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
AU5756298A (en) * 1997-04-18 1998-11-13 Gesellschaft Fur Biotechnologische Forschung Mbh Attenuated salmonella strain used as a vehicle for oral immunization
US5935816A (en) * 1997-07-23 1999-08-10 Smithkline Beecham Corporation Chlamydia trachomatis lysS polynucleotides
US6605287B2 (en) * 1997-08-28 2003-08-12 Board Of Supervisors Of Louisiana State University & Agricultural And Mechanical College Vaccines for Chlamydia psittaci infections
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
ES2352082T3 (es) * 1997-11-21 2011-02-15 Merck Serono Biodevelopment Polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección.
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
US20020064517A1 (en) * 1998-04-30 2002-05-30 Stewart A. Cederholm-Williams Fibrin sealant as a transfection/transformation vehicle for gene therapy
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
US20030147924A1 (en) * 1998-07-27 2003-08-07 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding dna fragments and uses thereof
US6660275B2 (en) * 1998-07-27 2003-12-09 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2336534A1 (en) * 1998-07-27 2000-02-10 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1105490A1 (de) * 1998-08-20 2001-06-13 Aventis Pasteur Limited Einschlussmembranprotein c von chlamydia kodierende nukleinsäuremoleküle
US6686339B1 (en) * 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) * 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6403101B1 (en) * 1998-10-28 2002-06-11 Connaught Laboratories Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6649370B1 (en) * 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6872814B2 (en) * 1998-10-29 2005-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) * 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US20020094340A1 (en) * 1998-12-01 2002-07-18 Andrew D. Murdin Chlamydia antigens and corresponding dna thereof
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
US6448234B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
JP2003512017A (ja) * 1998-12-23 2003-04-02 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US7297341B1 (en) * 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) * 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2356057A1 (en) * 1998-12-28 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1163342B1 (de) * 1999-03-12 2008-12-10 Aventis Pasteur Limited Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
JP4695763B2 (ja) * 1999-05-03 2011-06-08 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6225443B1 (en) * 1999-05-19 2001-05-01 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US6191259B1 (en) * 1999-05-19 2001-02-20 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
JP4667694B2 (ja) * 1999-09-20 2011-04-13 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6632663B1 (en) * 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU1375501A (en) * 1999-11-12 2001-05-30 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP4864264B2 (ja) * 1999-12-22 2012-02-01 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
AU2138601A (en) * 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2138501A (en) * 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) * 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020082402A1 (en) * 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094965A1 (en) * 2000-04-04 2002-07-18 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100706A1 (en) * 2000-04-04 2003-05-29 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20040254130A1 (en) * 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
JP3653219B2 (ja) * 2000-10-30 2005-05-25 シャープ株式会社 印刷装置およびそれを用いた通信装置または情報処理装置
BRPI0518109A (pt) * 2004-11-30 2008-11-04 Aeras Global Tb Vaccine Foundation cepa bacteriana, nucleocapsìdeo, preparação de vacina, método para criar uma bactéria recombinante, bactéria mutante, seqüências de rna fluorado para deslanchar rdsrna e meio para eletroporação

Also Published As

Publication number Publication date
JP2002531135A (ja) 2002-09-24
AU1540700A (en) 2000-06-26
DE69930147D1 (de) 2006-04-27
MXPA01005615A (es) 2004-08-19
US20080182320A1 (en) 2008-07-31
US20040126382A1 (en) 2004-07-01
US20020168382A1 (en) 2002-11-14
EP1169465A1 (de) 2002-01-09
DE69930147T2 (de) 2007-01-11
EP1169465B1 (de) 2006-03-01
AU772356B2 (en) 2004-04-22
CA2366462C (en) 2011-08-09
NZ512730A (en) 2003-12-19
US20040131630A1 (en) 2004-07-08
US20080095804A1 (en) 2008-04-24
WO2000034498A1 (en) 2000-06-15
US6676949B2 (en) 2004-01-13
US20090215151A1 (en) 2009-08-27
CA2366462A1 (en) 2000-06-15
US7026300B2 (en) 2006-04-11

Similar Documents

Publication Publication Date Title
MY104590A (en) Improvements in or relating to organic compounds.
MXPA02012352A (es) Vacuna para temblores congenitos en cerdos.
ATE269100T1 (de) Verfahren zur therapeutischen impfung
DE69637660D1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
CY1106926T1 (el) Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της
ATE352314T1 (de) Aktive immunisierung gegen ein siderophores rezeptorprotein
ATE318924T1 (de) Zwei-schritte-verfahren zur impfung gegen chlamydia
HUP0000992A2 (hu) Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
ATE167061T1 (de) Kreuzschützende salmonella impfstoffe
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
DE69527986D1 (de) Antigene arznei zur behandlung oder vorbeugung
DK0796104T3 (da) Levering af nukleinsyremolekyler til slimhindevæv
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
PT653489E (pt) Vacina contra a coccidiose em aves domesticas
ATE107516T1 (de) Pasteurella-impfstoff.
DE3582373D1 (de) Herstellung des e.coli-lt-b-enterotoxinunterteils.
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
RU95112808A (ru) Живая сальмонеллезная вакцина
AU2973800A (en) Dna vaccines against hantavirus infections
TW332199B (en) Process for the preparation of 3-chloropropionic acid
WO1992003553A1 (en) Footrot vaccine
ATE295884T1 (de) Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose
SE8205247D0 (sv) Fiskvacciner
ATE381612T1 (de) Verfahren zur fermentativen herstellung von l- aminosäuren mittels koryneformen bakterien
ATE406911T1 (de) Fisch-impfstoff

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties